Nicholas Adlard

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 16

Top Topics

Systematic Review

Monoclonal Antibody

Top Venues

PharmacoEconomics - open

Journal of comparative effectiveness research

ClinicoEconomics and outcomes research : CEOR

Journal of medical economics

This page only lists publications with an associated author ORCID identifier.

Publications

Richard St John Nicholas, Erik Scalfaro, Rachel Dorsey, Zuzanna Angehrn, Judit Banhazi, Roisin Brennan, Nicholas Adlard
ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario Simulation. PharmacoEconomics - open 8 (5) (2024)
Ralph H B Benedict, Pamela Vo, Nicholas Adlard, Olwyn Grennan, Ashley Enstone, Daisy Bridge, Robin Wyn, Stanley L Cohan
Disutility of Cognitive Processing Speed (CPS) Impairment in the Context of Multiple Sclerosis: A Time Trade-Off (TTO) Elicitation Study. ClinicoEconomics and outcomes research : CEOR 16 (2024)
Richard St John Nicholas, Erik Scalfaro, Rachel Dorsey, Zuzanna Angehrn, Judit Banhazi, Roisin Brennan, Nicholas Adlard
ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario Simulation. PharmacoEconomics - open (2024)
Richard St John Nicholas, Erik Scalfaro, Rachel Dorsey, Zuzanna Angehrn, Judit Banhazi, Roisin Brennan, Nicholas Adlard
ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario Simulation. PharmacoEconomics - open 8 (5) (2024)
Richard St John Nicholas, Erik Scalfaro, Rachel Dorsey, Zuzanna Angehrn, Judit Banhazi, Roisin Brennan, Nicholas Adlard
ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario Simulation. PharmacoEconomics - open 8 (5) (2024)
Ralph H B Benedict, Pamela Vo, Nicholas Adlard, Olwyn Grennan, Ashley Enstone, Daisy Bridge, Robin Wyn, Stanley L Cohan
Disutility of Cognitive Processing Speed (CPS) Impairment in the Context of Multiple Sclerosis: A Time Trade-Off (TTO) Elicitation Study. ClinicoEconomics and outcomes research : CEOR 16 (2024)
Sophi Tatlock, Kate Sully, Anjali Batish, Chelsea Finbow, William Neill, Carol Lines, Roisin Brennan, Nicholas Adlard, Tamara Backhouse
Individual Differences in the Patient Experience of Relapsing Multiple Sclerosis (RMS): A Multi-Country Qualitative Exploration of Drivers of Treatment Preferences Among People Living with RMS. The patient (2023)
Imtiaz A Samjoo, Susan Lavinia Greco, Sarah Walsh, Santosh Tiwari, Róisín Brennan, Ibolya Boer, Dieter A Häring, Luisa Klotz, Nicholas Adlard, Judit Banhazi
Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis. Journal of comparative effectiveness research (2023)
Umakanth Vudumula, Mausam Patidar, Kapil Gudala, Elizabeth Karpf, Nicholas Adlard
Evaluating the impact of early vs delayed ofatumumab initiation and estimating the long-term outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis patients in Spain. Journal of medical economics (2022)
Kristyna Lacinova, Praveen Thokala, Richard Nicholas, Pamela Dobay, Erik Scalfaro, Zuzanna Angehrn, Roisin Brennan, Ibolya Boer, Carol Lines, Nicholas Adlard
ENTIMOS: A Discrete Event Simulation Model for Maximising Efficiency of Infusion Suites in Centres Treating Multiple Sclerosis Patients. Applied health economics and health policy 20 (5) (2022)
Imtiaz A Samjoo, Evelyn Worthington, Anja Haltner, Paul Spin, Susan Lavinia Greco, Chris Cameron, Róisín Brennan, Frank Dahlke, Nicholas Adlard
Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses. Current medical research and opinion 37 (11) (2021)
Imtiaz A Samjoo, Evelyn Worthington, Susan Lavinia Greco, Melody Zhao, Chris Cameron, Dieter A Häring, Dee Stoneman, Luisa Klotz, Nicholas Adlard
Letter in reply. Journal of comparative effectiveness research 10 (17) (2021)
Jeremy Chataway, Niamh Murphy, Vivek Khurana, Helen Schofield, John Findlay, Nicholas Adlard
Secondary progressive multiple sclerosis: a systematic review of costs and health state utilities. Current medical research and opinion 37 (6) (2021)
Imtiaz A Samjoo, Evelyn Worthington, Susan Lavinia Greco, Melody Zhao, Chris Cameron, Dieter A Häring, Dee Stoneman, Luisa Klotz, Nicholas Adlard
Efficacy classification of modern therapies in multiple sclerosis. Journal of comparative effectiveness research 10 (6) (2021)
Imtiaz A Samjoo, Evelyn Worthington, Susan Lavinia Greco, Melody Zhao, Chris Cameron, Dieter A Häring, Dee Stoneman, Luisa Klotz, Nicholas Adlard
Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. Journal of comparative effectiveness research 9 (18) (2020)
Hamid Reza Nakhaipour, Umakanth Vudumula, Vivek Khurana, Guillaume Sébire, Jean K Mah, Daniela Pohl, Robyn Schecter, Nicholas Adlard
Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada. Journal of medical economics 23 (12) (2020)